Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone781-848-7100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$903.92 million
Profitability
Miscellaneous
Employees3,136
OptionableOptionable
Haemonetics (NYSE:HAE) Frequently Asked Questions
What is Haemonetics' stock symbol?
Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."
How will Haemonetics' stock buyback program work?
Haemonetics declared that its Board of Directors has authorized a stock repurchase program on Tuesday, February 6th 2018, which permits the company to repurchase $260,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company's management believes its stock is undervalued.
How were Haemonetics' earnings last quarter?
Haemonetics Co. (NYSE:HAE) posted its earnings results on Tuesday, November, 6th. The medical instruments supplier reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.02. The medical instruments supplier had revenue of $241.58 million for the quarter, compared to analysts' expectations of $233.44 million. Haemonetics had a net margin of 2.26% and a return on equity of 16.04%. The company's revenue was up 7.2% on a year-over-year basis. During the same period last year, the company earned $0.48 earnings per share. View Haemonetics' Earnings History.
When is Haemonetics' next earnings date?
How can I listen to Haemonetics' earnings call?
Haemonetics will be holding an earnings conference call on Tuesday, February 5th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8778488880.
What guidance has Haemonetics issued on next quarter's earnings?
Haemonetics issued an update on its FY19 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $2.25-2.35 for the period, compared to the Thomson Reuters consensus estimate of $2.29. The company issued revenue guidance of $958.2-$976.2 million, compared to the consensus revenue estimate of $951.91 million.Haemonetics also updated its FY 2018 guidance to $2.25-2.35 EPS.
What price target have analysts set for HAE?
4 brokers have issued 1-year price objectives for Haemonetics' shares. Their forecasts range from $72.00 to $127.00. On average, they expect Haemonetics' share price to reach $111.00 in the next twelve months. This suggests a possible upside of 10.0% from the stock's current price. View Analyst Price Targets for Haemonetics.
What is the consensus analysts' recommendation for Haemonetics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.
What are Wall Street analysts saying about Haemonetics stock?
Here are some recent quotes from research analysts about Haemonetics stock:
- 1. According to Zacks Investment Research, "Over the past year, Haemonetics has been outperforming its industry. Per the company, benefits from complexity reduction and investments along with strength in market demand and success from early launches helped it perform impressively in the last reported quarter. Continued momentum in new business generation and geographical expansion has contributed to the results as well. Meanwhile, we are upbeat about the company’s steady progress with the ongoing rollout of NexSys PCS devices and NexLynk DMS donor management software. However, we are disappointed with the fact that despite encouraging growth at the Plasma and Hospitals segments, the company’s sluggish Blood Center business moderated overall growth in the reporting cycle." (1/8/2019)
- 2. Barrington Research analysts commented, "We believe that a full transition of the company’s 20,000 base could add $2 or more per plasma donation (i.e. $70 million plus)." (10/5/2018)
- 3. Morgan Stanley analysts commented, "We are maintaining our Outperform rating for REGENXBIO. Today, after market close, the company reported 1Q18 results and provided an update on its pipeline. Key takeaways include: 1) all programs remain on track, with topline data from both the wet AMD and HoFH trials expected in late 2018; and 2) the two MPS programs are slated to dose the first patients in mid-2018. With two wholly owned assets poised to deliver clinical data in late 2018, a powerful AAV technology platform with >20+ partnered programs (10 of which are in the clinic), and a cash position of $336 million pro forma, we continue to recommend REGENXBIO shares to risk-tolerant investors." (5/9/2018)
Has Haemonetics been receiving favorable news coverage?
News headlines about HAE stock have trended somewhat positive this week, InfoTrie reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Haemonetics earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the near future.
Who are some of Haemonetics' key competitors?
Some companies that are related to Haemonetics include ResMed (RMD), ABIOMED (ABMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Insulet (PODD), Globus Medical (GMED), Novocure (NVCR), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM) and NuVasive (NUVA).
Who are Haemonetics' key executives?
Haemonetics' management team includes the folowing people:
- Mr. Christopher Simon, CEO, Pres & Director (Age 55)
- Mr. William P. Burke, CFO & Exec. VP
- Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec.
- Ms. Jacqueline D. Scanlan, Sr. VP of Global HR
- Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 42)
Who are Haemonetics' major shareholders?
Haemonetics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BTIM Corp. (0.29%), Retirement Systems of Alabama (0.13%), Dorsey Wright & Associates (0.08%), Louisiana State Employees Retirement System (0.03%), Cardinal Capital Management (0.02%) and Bowling Portfolio Management LLC (0.01%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote, Willaim P Burke and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.
Which institutional investors are selling Haemonetics stock?
HAE stock was sold by a variety of institutional investors in the last quarter, including BTIM Corp., Nisa Investment Advisors LLC, Bowling Portfolio Management LLC, Louisiana State Employees Retirement System and First Hawaiian Bank. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia and William P Mr Burke. View Insider Buying and Selling for Haemonetics.
Which institutional investors are buying Haemonetics stock?
HAE stock was acquired by a variety of institutional investors in the last quarter, including Dorsey Wright & Associates, Cerebellum GP LLC, First Citizens Bank & Trust Co., Retirement Systems of Alabama and Cardinal Capital Management. View Insider Buying and Selling for Haemonetics.
How do I buy shares of Haemonetics?
Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Haemonetics' stock price today?
One share of HAE stock can currently be purchased for approximately $100.92.
How big of a company is Haemonetics?
Haemonetics has a market capitalization of $5.15 billion and generates $903.92 million in revenue each year. The medical instruments supplier earns $45.57 million in net income (profit) each year or $1.87 on an earnings per share basis. Haemonetics employs 3,136 workers across the globe.
What is Haemonetics' official website?
How can I contact Haemonetics?
Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]
MarketBeat Community Rating for Haemonetics (NYSE HAE)
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.
